Meyka Pro banner
Evolus, Inc.

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EOLSNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$8.21
$0.13(1.56%)
U.S. Market is Open · 14:50

Evolus, Inc. (EOLS)

Meyka AI Score

Z

Key Financials

Market Cap534.7M
P/E Ratio-15.76
EPS (TTM)$-0.32
ROE1.23%
Fundamental Analysis

AI Price Forecasts

1 Month$7.02
3 Months$6.26
1 Year Target$0.46

EOLS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Evolus, Inc. (NASDAQ: EOLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Evolus, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of EOLS on the NASDAQ shows an RSI of 73.08, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $0.46 for the NASDAQ listing.

Key metrics behind Evolus, Inc.'s NASDAQ-traded stock include a P/E ratio of -15.76 and a market capitalization of 534.7M. Combined with our AI analysis, these give both institutional and retail investors a clear view of EOLS on the NASDAQ.

Price Performance (NASDAQ: EOLS)

1-Day Change
-2.64%
5-Day Change
11.54%
1-Month Change
22.84%
3-Month Change
24.92%
6-Month Change
89.72%
Year-to-Date (YTD) Change
22.11%
1-Year Change
26.88%
3-Year Change
-16.97%
5-Year Change
-24.61%
All-Time (Max) Change
-29.39%

Contact Information

949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

3,340 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions